vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $80.1M, roughly 1.1× AMERISAFE INC). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 10.2%, a 12.6% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 10.3%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
AMSF vs FDMT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $85.1M |
| Net Profit | $8.1M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | — | 17.3% |
| Net Margin | 10.2% | 22.8% |
| Revenue YoY | 10.3% | 8508900.0% |
| Net Profit YoY | -9.0% | 139.1% |
| EPS (diluted) | $0.43 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $85.1M | ||
| Q3 25 | $82.0M | $90.0K | ||
| Q2 25 | $81.1M | $15.0K | ||
| Q1 25 | $72.6M | $14.0K | ||
| Q4 24 | $74.0M | $1.0K | ||
| Q3 24 | $78.7M | $3.0K | ||
| Q2 24 | $75.8M | $5.0K |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | $19.4M | ||
| Q3 25 | $13.8M | $-56.9M | ||
| Q2 25 | $14.0M | $-54.7M | ||
| Q1 25 | $8.9M | $-48.0M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $14.3M | $-43.8M | ||
| Q2 24 | $11.0M | $-35.0M |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 17.3% | ||
| Q3 25 | 21.3% | -67983.3% | ||
| Q2 25 | 21.5% | -396373.3% | ||
| Q1 25 | 15.5% | -383007.1% | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 22.6% | -1704400.0% | ||
| Q2 24 | 18.1% | -849120.0% |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | 22.8% | ||
| Q3 25 | 16.9% | -63195.6% | ||
| Q2 25 | 17.2% | -364386.7% | ||
| Q1 25 | 12.3% | -342657.1% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 18.2% | -1461433.3% | ||
| Q2 24 | 14.5% | -699060.0% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $0.43 | ||
| Q3 25 | $0.72 | $-1.01 | ||
| Q2 25 | $0.73 | $-0.98 | ||
| Q1 25 | $0.47 | $-0.86 | ||
| Q4 24 | $0.69 | — | ||
| Q3 24 | $0.75 | $-0.79 | ||
| Q2 24 | $0.57 | $-0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $505.7M |
| Total Assets | — | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $402.7M | ||
| Q3 25 | $54.7M | $305.1M | ||
| Q2 25 | $48.5M | $293.2M | ||
| Q1 25 | $44.8M | $321.4M | ||
| Q4 24 | $44.1M | $424.9M | ||
| Q3 24 | $63.7M | $501.9M | ||
| Q2 24 | $30.6M | $541.9M |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $505.7M | ||
| Q3 25 | $274.8M | $369.0M | ||
| Q2 25 | $265.6M | $420.9M | ||
| Q1 25 | $260.8M | $469.7M | ||
| Q4 24 | $257.3M | $510.6M | ||
| Q3 24 | $314.4M | $552.9M | ||
| Q2 24 | $301.0M | $588.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $566.7M | ||
| Q3 25 | $1.2B | $424.0M | ||
| Q2 25 | $1.2B | $473.6M | ||
| Q1 25 | $1.2B | $515.7M | ||
| Q4 24 | $1.2B | $560.4M | ||
| Q3 24 | $1.3B | $604.0M | ||
| Q2 24 | $1.2B | $620.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $28.6M | ||
| Q3 25 | $10.7M | $-46.5M | ||
| Q2 25 | $-8.4M | $-43.4M | ||
| Q1 25 | $-1.8M | $-47.8M | ||
| Q4 24 | $24.2M | $-134.6M | ||
| Q3 24 | $8.4M | $-29.4M | ||
| Q2 24 | $-2.6M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | $28.5M | ||
| Q3 25 | $9.8M | $-46.6M | ||
| Q2 25 | $-9.5M | $-43.4M | ||
| Q1 25 | $-1.8M | $-48.4M | ||
| Q4 24 | $23.4M | $-138.4M | ||
| Q3 24 | $8.4M | $-31.2M | ||
| Q2 24 | $-2.6M | $-30.6M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 33.5% | ||
| Q3 25 | 11.9% | -51765.6% | ||
| Q2 25 | -11.7% | -289620.0% | ||
| Q1 25 | -2.5% | -345635.7% | ||
| Q4 24 | 31.5% | -13837100.0% | ||
| Q3 24 | 10.7% | -1038966.7% | ||
| Q2 24 | -3.5% | -611840.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 1.1% | 101.1% | ||
| Q2 25 | 1.3% | 440.0% | ||
| Q1 25 | 0.0% | 4507.1% | ||
| Q4 24 | 1.1% | 378600.0% | ||
| Q3 24 | 0.0% | 59266.7% | ||
| Q2 24 | 0.1% | 6980.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | 1.47× | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
